| Name | (S)-Thalidomide |
| Description | (S)-Thalidomide ((S)-(-)-Thalidomide) is the S-isomer of Thalidomide with immunomodulatory, anti-inflammatory, anticancer, anti-angiogenic, and pro-apoptotic activities, used in studying leprosy erythema nodosum and myeloma. |
| In vitro | In U266 cells cultured with (S)-Thalidomide, a decrease in cell viability (IC50: 362 μM) was observed, reflecting a significant increase in apoptosis (for example, on the 3rd day at 200 μM: 40.3+/-3.1% vs. 3.2+/-0.4% on the 0th day; P<0.001). Furthermore, the expression profile of genes involved in angiogenesis and apoptosis changed, with the most significant alterations observed in the expression of apoptosis-related genes[1]. |
| In vivo | Direct exposure of embryos to (S)-Thalidomide does indeed result in limb reduction defects in chick embryos. (S)-Thalidomide affects chick limb transplantation into host embryos in a dose-dependent manner. Moreover, S-thalidomide and S-EM12 are more teratogenic than R-thalidomide and R-EM12[2]. |
| Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 60 mg/mL (232.35 mM), Sonication is recommended.
|
| Keywords | (S) Thalidomide | Thalidomide | (S)Thalidomide |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Acetylcysteine | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin |
| Related Compound Libraries | Bioactive Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |
United States
